Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors

The absence of an adequate reversal strategy to prevent and stop potential life-threatening bleeding complications is a major drawback to the clinical use of the direct oral inhibitors of blood coagulation factor Xa. Here we show that specific modifications of the substrate-binding aromatic S4 subpo...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Nat Commun
Asıl Yazarlar: Verhoef, Daniël, Visscher, Koen M., Vosmeer, C. Ruben, Cheung, Ka Lei, Reitsma, Pieter H., Geerke, Daan P., Bos, Mettine H. A.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group UK 2017
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5597622/
https://ncbi.nlm.nih.gov/pubmed/28904343
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-017-00647-9
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller